Effects of ivabradine therapy on heart failure biomarkers

Cardiology Journal

Volumn 22, Issue 5, 2015, Pages 501-509

  Ordu, Serkan ^a   Yildiz, Bekir Serhat ^b   Alihanoglu, Yusuf Izzettin ^b   Ozsoy, Aybars ^a   Tosun, Mehmet ^c   Evrengul, Harun ^b   Kaftan, Havane Asuman ^b   Ozhan, Hakan ^d  

^a Department of Biochemsitry Kastamonu Private Anadolu Hospital   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

^c ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^d DUZCE UNIVERSITY   (Turkey)

Author keywords

CA 125; Cystatin C; Ivabradine; NT proBNP; Systolic heart failure

Indexed keywords

BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CA 125 ANTIGEN; CREATININE; CYSTATIN C; IVABRADINE; BENZAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CST3 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ASSESSMENT; DEMOGRAPHY; DISEASE ASSOCIATION; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEW YORK HEART ASSOCIATION CLASS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; AGED; BLOOD; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECTS; FEMALE; HEART FAILURE, SYSTOLIC; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TURKEY;

AGED; BENZAZEPINES; BIOMARKERS; CA-125 ANTIGEN; CARDIOVASCULAR AGENTS; CYSTATIN C; DOWN-REGULATION; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; TURKEY; VENTRICULAR FUNCTION, LEFT;

EID: 84944116507     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2015.0012     Document Type: Article

References (38)

1. NICE. Chronic Heart Failure — National clinical guideline for diagnosis and management in primary and secondary care. 2010
2. Spinale FG, Zellner JL, Tomita M et al. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia induced cardiomyopathy. Circ Res, 1991; 69: 1058–1067
3. Cooney MT, Vartiainen E, Laakitainen T et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J, 2010; 159: 612–619
4. Bohm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, 2010; 376: 886–894
5. Hoke RS, Muller-Werdan U, Lautenschlager C et al. Heart rate as an independent risk factor in patients with multiple organ dysfunction: A prospective, observational study. Clin Res Cardiol, 2012; 101: 139–147
6. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J, 1999; 1: H64–H69
7. Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation, 2001; 103: 1428–1433
8. Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet, 1993; 342: 1441–1446
9. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs, 2004; 64: 1757–1765
10. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebocontrolled trial. Lancet, 2010; 376: 875–885
11. Tardif JC, O’Meara E, Komajda M et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. Eur Heart J, 2011; 32:2507-15
12. Ekman I, Chassany O, Komajda M et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: Results from the SHIFT study. Eur Heart J, 2011; 32: 2395–2404
13. Volterrani M, Cice G, Caminiti G et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (The CARVIVA HF trial). Int J Cardiol, 2011; 151: 218–224
14. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: betablocker dose, heart rate reduction, and death in patients with heart failure. Ann Inter Med, 2009; 150: 784–794
15. Triposkiadis F, Karayannis G, Giamouzis G et al. The sympa - thetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol, 2009; 54: 1747–1762
16. Busseuil D, Shi Y, Mecteau M et al. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology, 2010; 117: 234–242
17. Mulder P, Barbier S, Chagraoui A et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation, 2004; 109: 1674–1679
18. Ceconi C, Comini L, Suffredini S et al. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol, 2010; 300: 366–373
19. Milliez P, Messaoudi S, Nehme J et al. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol, 2009; 296: 435–441
20. Vercauteren M, Favre J, Mulder P et al. Protection of endothelial function by long-term heart rate reduction induced by ivabradine in a rat model of chronic heart failure. Eur Heart J, 2007; 28: 468
21. Ceconi C, Freedman SB, Tardif JC et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol, 2011; 146: 408–414
22. Maisel A, Mueller C, Adams K Jr et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail, 2008; 10: 824–839
23. Rosenberg J, Gustafsson F, Remme WJ et al. Effect of betablockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther, 2008; 22: 305–311
24. White M, Rouleau JL, Afzal R et al. Effects of enalapril, candersartran or both on neurohormonal activation and LV volumes and function in patients with heart failure not treated with beta- -blocker. Ther Adv Cardiovasc Dis, 2009; 3: 113–121
25. Berry C, Murphy NF, De Vito G et al. Effects of aldosterone receptor blockage in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail, 2007; 9: 429–434
26. Masson S, Latini R, Anand IS et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Vaal-HeFT (Valsartran Heart Failure Trial). J Am Coll Cardiol, 2008; 52: 997–1003
27. Sargento L, Satendra M, Longo S et al. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure. Clin Cardiol, 2013; 36: 677–682
28. Coll E, Botey A, Alvarez L et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis, 2000; 36: 29–34
29. Gao C, Zhong L, Gao Y et al. Cystatin C levels are associated with the prognosis of systolic heart failure patients. Arch Cardiovasc Dis, 2011; 104: 565–571
30. Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med, 2006; 145: 237–246
31. Dupont M, Wu Y, Hazen SL et al. Cystatin C ıdentifies patients with stable chronic heart failure at ıncreased risk for adverse cardiovascular events. Circ Heart Fail, 2012; 5: 602–609
32. Miralles C, Orea M, Espana P et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol, 2003; 10: 150–154
33. D’Aloia A, Faggiano P, Aurigemma G et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and shortterm prognosis. J Am Coll Cardiol, 2003; 41: 1805–1811
34. Colombo PC, Ganda A, Lin J et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev, 2012; 17: 177–190
35. Varol E, Ozaydin M, Dogan A et al. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail, 2005; 7: 840–843
36. Turk HM, Pekdemir H, Buyukberber S et al. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol, 2003; 24: 172–175
37. Nunez J, Nunez E, Consuegra L et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart, 2007; 93: 716–721
38. Folga A, Filipiak KJ, Mamcarz A et al. Simultaneous predictive value of NT-proBNP and CA-125 in patients newly diagnosed with advanced heart failure: Preliminary results. Arch Med Sci, 2012; 8: 637–643.